Triple-negative breast cancer (also called TNBC) is a type of breast cancer that does not respond to the same anticancer treatments as other types of breast cancers because the cancer cells are missing three more common types of receptors found on other types of breast cancer cells.

Up to 20% of all breast cancers are triple-negative. Unfortunately, triple-negative breast cancer is often not diagnosed early and is difficult to treat. Triple-negative breast cancer is more likely to affect younger people, particularly African-Americans and Hispanics and those with a certain gene mutation called BRCA1.

The good news is that doctors and researchers continue to learn more about triple-negative breast cancer. New discoveries and improved treatments are available to sometimes cure it if it is found early and to help slow down the disease if it is more advanced and spreads into other places in your body.

ELIGIBILITY CRITERIA

• At least 18 years old and diagnosed with triple-negative breast cancer
• Have triple-negative breast cancer that is metastatic (has spread in the body)
• Already have had at least one other treatment that did not stop the cancer from spreading or worsening

Non-Small Cell Lung Cancer (also referred to as NSCLC) is the most common type of lung cancer. There are three main subtypes of non-small cell lung cancer based on their microscopic picture. Although, they are different, most of the subtypes of non-small cell lung cancer usually respond to the same forms of treatment.

Non-small cell lung cancer occurs more frequently in black men than white men, but white women are more likely to develop the disease than black women. Non-small cell lung cancer is a difficult cancer to treat, however, important advances in the treatment include surgery, systemic therapy and radiotherapy, which have been shown to improve survival and even allow a cure, particularly if the cancer is detected early before it spreads throughout the body. However, if the disease becomes more advanced and spreads to other areas of your body it can become more difficult to treat.

Immunicom has joined the efforts of doctors and researchers to find new and better ways to treat non-small cell lung cancer. We presently have two clinical research studies being conducted, one in Israel and another in Turkey, that are actively recruiting patients diagnosed with advanced non-small cell lung cancer. Additional information about non-small cell lung cancer can be found at these websites:

ELIGIBILITY CRITERIA

• At least 18 years old and diagnosed with non-small cell lung cancer
• Have non-small cell lung cancer that is metastatic (has spread in the body)
• Already have had at least one other treatment that did not stop the cancer from spreading or worsening

Renal Cell Carcinoma (also referred to as renal cell cancer or RCC) is the most common type of kidney cancer. There are many types of renal cell cancers and you may have more than one type at the same time.

The most common type of renal cell carcinoma is called ‘clear cell’ and is due to a genetic mutation. Other types are believed to be hereditary and may be passed along in families from one generation to another. The clear cell type has the most treatment options, while the rare, unclassified type, is difficult to treat. There is even a type that is benign (not a cancerous tumor) and does not spread.

Treatment depends on the type(s) of renal cell carcinoma you have. Sometimes, no treatment is recommended if it will not spread. However, the earlier the renal cell carcinoma is detected, the better chance you have of controlling or curing the disease. Many renal cell cancers often can be treated with surgery by removing part of or the entire affected kidney. In more advanced cases, if the disease has spread to other parts of your body, there are other treatments such as chemotherapy, targeted therapy and immunotherapy drugs, as well as combinations of these treatments.

Immunicom is committed to helping doctors and researchers find new treatments for renal cell carcinoma.

Additional information about renal cell carcinoma can be found at these websites:

ELIGIBILITY CRITERIA

• At least 18 years old and diagnosed with renal cell carcinoma
• Have renal cell carcinoma that is metastatic (has spread in the body)
• Already have had at least one other treatment that did not stop the cancer from spreading or worsening

Melanoma is primarily found on your skin and although is not a common type of skin cancer, it can be the most challenging to treat. In up to 10% of cases, Melanoma also can occur in your mouth or even your eye.

The number of cases of melanoma continues to increase worldwide and is increasing faster (and is the second most common type of cancer) in younger women. Melanoma is more common in women than men under the age of 50, but much more common in men in age groups more than 50 years old. Melanoma is far more common in individuals who are white than in people of color; however, it is often not diagnosed early in people of color.

If detected early, melanoma often can be cured by surgically removing the cancer from the skin. Once it has spread, it is more difficult to treat. However, many years of hard work by doctors and researchers are now producing new types of drugs called targeted therapies and immunotherapy agents, that attack melanoma in different ways and can greatly improve survival, even in advanced stages of the disease. Other treatments continue to be studied.

Immunicom is involved in finding new ways to treat melanoma. We have a clinical research study in Israel that is actively recruiting patients diagnosed with advanced melanoma.

Additional information about melanoma can be found at these websites:

ELIGIBILITY CRITERIA

• At least 18 years old and diagnosed with melanoma
• Have melanoma that is metastatic (has spread in the body)
• Already have had at least one other treatment that did not stop the cancer from spreading or worsening